← Human Trials & Peer-Reviewed Studies
Attention-enhancing effects of propranolol and synergistic effects with nicotine.
Plain-language guide to PMID 32405757 (2020): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 32405757
- Journal
- Cognitive, affective & behavioral neuroscience
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Hahn B et al. (5 authors)
- DOI
- 10.3758/s13415-020-00794-5
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
The present study was designed to test whether this mechanism held true in humans, thus guiding development of novel nicotinic agonists for cognitive enhancement.
Why It Was Studied
In previous studies designed to identify the secondary neurotransmitter systems mediating nicotine's attention-enhancing effects in a rat model, the β-adrenoceptor antagonist propranolol blocked these effects.
Over four test days, each participant received double-placebo, nicotine only, propranolol only, and nicotine plus propranolol in randomized sequence before cognitive testing.
Who Took Part
The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
What Was Measured
In previous studies designed to identify the secondary neurotransmitter systems mediating nicotine's attention-enhancing effects in a rat model, the β-adrenoceptor antagonist propranolol blocked these effects.
Over four test days, each participant received double-placebo, nicotine only, propranolol only, and nicotine plus propranolol in randomized sequence before cognitive testing.
Topics PubMed links to this paper include Adrenergic beta-Antagonists, Attention, Cholinergic Agonists, Drug Synergism, Nicotine, Propranolol and Psychomotor Performance.
Author keywords: Arousal, POMS, RVIP, SARAT and Sustained attention.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2020 (Cognitive, affective & behavioral neuroscience), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.